Treatment With Local PPARgamma Ligand in Distal Ulcerative Colitis

Status

UNKNOWN

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00309660

Enrollment

Registered

2006-04-03

Start date

2005-11-30

Completion date

2007-06-30

Last updated

2006-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative Colitis

Keywords

PPARgamma ligand, Rosiglitazone, Enema

Brief summary

Treatment with PPARgamma ligands have been shown to reduces intestinal inflammation in murine models of colitis. The aim of this study was to evaluate the effect of treatment with local PPARgamma ligand (rosiglitazone) in distal ulcerative colitis.The patients are treated with rosiglitazone enema, once a day, for fourteen days. Disease activity was assessed before and after treatment by endoscopical and clinical activity score.

Interventions

DRUGRosiglitazone

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Distal ulcerative colitis (Mayo Clinical Score \> 7) * Age \> 18 years * Written consent

Exclusion criteria

* Age \< 18 years * Severe ulcerative colitis * Systemic treatment with steroids or azathioprin within the last 3 month * Known liver or kidney disease * Severe heart failure * Pregnancy or breast feeding

Design outcomes

Primary

Measure	Time frame
Clinical response	—

Secondary

Measure	Time frame
Endoscopic response	—

Countries

Denmark

Contacts

Primary ContactGitte Pedersen

gitped01@herlevhosp.kbhamt.dk+ 45 44883418

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026